IRIDEX Corporation — Q2 2017 Form 10-Q
Business context and period. IRIDEX develops and sells ophthalmic medical lasers, delivery devices, consumables, and service contracts. This unaudited quarterly report covers the three and six months ended July 1, 2017; the three-month periods each contained 13 weeks. Financial amounts below are in U.S. dollars; “million” amounts are rounded.
Financial performance and liquidity
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Revenue | $10.0m | $11.9m | $20.5m | $23.8m |
| Gross profit / margin | $4.5m / 44.9% | $5.7m / 48.2% | $9.0m / 43.7% | $11.0m / 46.3% |
| Operating expenses | $7.2m | $6.1m | $13.6m | $11.3m |
| Operating loss | $2.7m | $0.4m | $4.6m | $0.2m |
| Net loss | $2.8m | $0.3m | $4.6m | $0.2m |
| Basic and diluted loss per share | $0.24 | $0.03 | $0.40 | $0.02 |
- Revenue and mix: Q2 revenue fell 16.0% year over year. Domestic system sales declined 38.4%, international system sales 15.3%, and recurring revenue 5.3%. For the first half, revenue fell 14.1%; domestic and international system sales declined 23.6% and 27.1%, respectively, while recurring revenue decreased 1.0%.
- Margins and expenses: Gross margin fell 3.3 percentage points in Q2 and 2.5 points for the first half. Management attributed the declines mainly to lower manufacturing overhead absorption from reduced sales; Q2 also reflected manufacturing variances, including inventory and warranty reserves. Sales and marketing expense rose 51.9% in Q2 and 36.1% for the first half, primarily with hiring, commissions, recruiting, and selling costs. R&D also increased.
- Cash flow: First-half operating cash use was $0.7m, versus $1.8m provided in the prior-year period. Investing used $0.6m, including $0.4m of capital expenditures and $0.2m in earn-out payments. Financing provided $2.2m, including $2.3m net proceeds from common-stock issuance. Cash increased by $0.8m to $24.6m.
- Liquidity and debt: At July 1, cash was $24.6m, current assets $43.5m, current liabilities $7.8m, and working capital $35.8m. The company reported no fixed- or variable-rate debt outstanding. Management said existing cash and cash equivalents should meet anticipated cash needs for the next 12 months.
Material changes, outlook, and risks
- Revenue declines were concentrated in system sales, particularly medical and surgical retina products; recurring revenue was comparatively more stable. Management cited lower EndoProbe revenue and, in the first half, partially offsetting growth in G6-related probes.
- The company expanded its sales organization and was establishing direct sales capabilities in Germany. Management cautioned that recruiting and training can take time and that spending may rise before new representatives generate revenue.
- IRIDEX began offering a five-year warranty on IQ 532/577 laser-console laser heads in March 2017, compared with prior one-to-two-year product warranties. Warranty liability was $0.7m at July 1, 2017; actual future claims may differ from estimates.
- Contractual obligations totaled $13.3m: $5.9m in operating lease payments and $7.4m in purchase commitments. No material off-balance-sheet arrangements were reported.
- No specific revenue or earnings guidance was provided. Management expects gross margins to continue fluctuating with sales geography and mix, new products, manufacturing variances, and production volume.
- Key disclosed risks include declining demand or delayed customer purchases, competitive pressure, reliance on distributors and limited-source suppliers, manufacturing and product-quality issues, sales-force execution, regulatory and reimbursement requirements, international-market exposure, and the ability to develop and gain acceptance for new products. Litigation matters were described as ordinary-course matters not currently expected to have a material adverse effect. The annual goodwill impairment test in Q2 found no impairment; the earn-out liability was $0.6m and depends on projected royalties and discount-rate assumptions.
- Management concluded disclosure controls and procedures were effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported.
Most important facts for investors to verify
- Whether system-sales declines stabilize and whether G6-related probe growth can offset weakness in other product lines.
- Whether expanded sales and marketing investment produces sufficient revenue to improve operating performance and gross margins.
- Cash consumption against management’s 12-month liquidity assessment, including the timing of contractual commitments and any need for additional capital.
- Potential costs and claims associated with the new five-year warranty, and the assumptions underlying the earn-out liability.
- Progress in Germany and other markets, and developments involving product quality, supply, regulatory compliance, and reimbursement.